Working... Menu

Efficacy of S-Adenosylmethionine in Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00528710
Recruitment Status : Completed
First Posted : September 12, 2007
Last Update Posted : September 12, 2007
Information provided by:
Deakin University

Brief Summary:

Fundamentally, the trial aims to conduct a gold-standard test of the clinical impact of SAM-e in the treatment of depressed mood and general symptoms of fibromyalgia (FMS).

As such, salient clinical and pathological parameters will be assessed over an 8-week period in 60 patients who will be provided with either SAM-e or a placebo preparation . On the basis of previous literature, it is hypothesised that patients in the active treatment group will experience moderate but significant improvements across the clinical measures, and that these gains will be significantly greater than any reported in the placebo group. All patients will provide informed consent. All procedures will be conducted under medical supervision and the preparation itself is very safe when used in the manner proposed for the trial

Condition or disease Intervention/treatment Phase
Fibromyalgia Syndrome Dietary Supplement: SAM-e (S-Adenosyl-L-Methionine) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia
Study Start Date : November 2006
Actual Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia

Arm Intervention/treatment
Placebo Comparator: P
Placebo Control Group
Dietary Supplement: SAM-e (S-Adenosyl-L-Methionine)
One 400 mg tablet daily in the morning.

Primary Outcome Measures :
  1. Symptom reduction in Fibromyalgia. Specifically we expect a reduction in depressive symptoms, sleep disturbances and gastric disturbances. [ Time Frame: Measured at three points in time: pre-trial and at 4 and 8 weeks ]

Secondary Outcome Measures :
  1. Examination of dose-response data and the nature of the placebo effect in these conditions. [ Time Frame: Measured at three points in time: pre-trial and at 4 and 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Fibromyalgia by a medical practitioner

Exclusion Criteria:

  • Pregnancy, Manic and hypomanic conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00528710

Layout table for location information
Australia, Victoria
Deakin University
Burwood, Victoria, Australia, 3125
Sponsors and Collaborators
Deakin University
Layout table for investigator information
Principal Investigator: Gregory A Tooley, PhD Deakin University

Layout table for additonal information Identifier: NCT00528710     History of Changes
Other Study ID Numbers: DUHREC06
First Posted: September 12, 2007    Key Record Dates
Last Update Posted: September 12, 2007
Last Verified: September 2007

Keywords provided by Deakin University:

Additional relevant MeSH terms:
Layout table for MeSH terms
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases